- Women with a pathogenic mutation of the BRCA2 gene or othergenes who are at moderate or high risk for breast cancer, as well as those whohave not been tested but have first-degree relatives who are carriers, shouldundergo annual MRI after the diagnosis of the mutation but not before theage of 30 (category A). This evidence concerns the gene BRCA2 and breast cancer.